Latest news with #BurjeelHoldings'
Zawya
17-04-2025
- Business
- Zawya
Burjeel Holdings, Hippocratic AI partner to advance generative AI healthcare agents
Burjeel Holdings today announced a strategic partnership with Hippocratic AI, the company that pioneered the first safety-focused generative AI healthcare agents, to transform healthcare delivery through safe, scalable, and empathetic AI. The initiative kicked off during the Abu Dhabi Global Healthcare Week. The collaboration will see Hippocratic AI's generative AI healthcare agents, built for patient-facing non-diagnostic clinical tasks, deployed across Burjeel Holdings' hospitals, medical centres, and physiotherapy clinics in the UAE and Oman. By integrating Hippocratic AI's cutting-edge AI capabilities, Burjeel Holdings aims to transform the patient engagement experience, providing personalised and compassionate clinical conversations that address patient needs. Their introduction aligns with the Group's commitment to integrating advanced technology in healthcare while maintaining a human-centric approach. John Sunil, Group Chief Executive Officer of Burjeel Holdings, said, "At Burjeel Holdings, we believe that the future of healthcare lies in the perfect harmony between cutting-edge technology and personalised care. Our partnership with Hippocratic AI is a testament to our ongoing mission to leverage AI to improve patient experience, efficiency, reduce wait times, and ultimately provide better health outcomes for our patients." What sets these agents apart is their ability to engage in natural, safety-focused, human-like conversations. Through the integration of Hippocratic AI's multilingual, empathy-driven agents, Burjeel Holdings will deliver real-time, culturally aware support across a wide range of patient touchpoints, including appointment scheduling, patient education, health risk assessments, and follow-up check ins. These advanced agents are capable of sustained, multi-turn dialogue, enabling them to provide consistent, compliant, and compassionate communication that enhances both the patient experience and care continuity. Munjal Shah, Co-Founder and CEO of Hippocratic AI, said, "This partnership supports our shared mission of achieving healthcare abundance. Our empathic genAI agents are designed to create a more compassionate and effective patient experience. Together, we will tailor our solutions to meet the specific needs of the communities we serve." Key highlights of the partnership include the deployment of multilingual AI agents, including Arabic and the Emirati dialect, ensuring effective communication with the region's diverse patient population. The collaboration will also deliver customised regional generative AI agents tailored for cultural alignment and local relevance, enhancing the quality and empathy of patient interactions. In addition, AI agents will be deployed across key specialities such as oncology, cardiology, neurology, and orthopaedics, supporting both clinical and administrative tasks to help streamline operations and elevate the patient experience. The partnership focuses on expanding the deployment of these genAI healthcare agents across Burjeel Holdings' facilities, ensuring that healthcare providers can access the latest advancements in technology and patient support. Incorporating AI technologies into the complex care environment aligns with Burjeel Holdings' commitment to transforming healthcare delivery across critical areas. This collaboration reflects a shared vision: harnessing safety-focused generative AI to support healthcare systems, ease staffing challenges, and deliver hyper-personalised, compassionate care - advancing the collective goal of healthcare abundance.
Zawya
17-04-2025
- Business
- Zawya
Multilingual, empathy-driven AI healthcare agents announced at Abu Dhabi Global Health Week
Palo Alto/Abu Dhabi: In a significant leap towards establishing an integrated innovation ecosystem, Burjeel Holdings and US-based Hippocratic AI have announced a strategic partnership aimed at transforming healthcare delivery through safe, scalable, and empathetic AI at Abu Dhabi Global Health Week. What sets these agents apart is their ability to engage in natural, safety-focused, human-like conversations. Through the integration of Hippocratic AI's multilingual, empathy-driven agents, Burjeel Holdings will deliver real-time, culturally aware support across a wide range of patient touchpoints, including appointment scheduling, patient education, health risk assessments, and follow-up check-ins. These advanced agents are capable of sustained, multi-turn dialogue, enabling them to provide consistent, compliant, and compassionate communication that enhances both the patient experience and care continuity. Hippocratic AI's agents already speak over 15 widely used languages such as Spanish, Mandarin, and Vietnamese, as well as more localized dialects like Emirati Arabic, with plans to expand linguistic coverage to nearly all major global languages. The collaboration will also deliver customized regional generative AI agents tailored for cultural alignment and local relevance, enhancing the quality and empathy of patient interactions. The AI agents will be deployed across key specialties such as oncology, cardiology, neurology, and orthopedics, supporting both clinical and administrative tasks to help streamline operations and elevate the patient experience. Hippocratic AI, the company that pioneered the first safety-focused generative AI healthcare agents, recently unveiled its patented Polaris 3.0, its most advanced and safety-focused constellation architecture to date. Built on extensive real-world insights from both patients and healthcare providers. With over 1.85 million patient calls and collaborations with more than 25 healthcare enterprise partners, it has set a new benchmark in patient safety and satisfaction, achieving a clinical accuracy rate of 99.38% and a record-high patient experience rating of 8.95 out of 10. At the core of the Polaris constellation system are specialized supervisor models that oversee critical areas such as medications, labs and vitals, nutrition, escalation protocols, and hospital-specific policies. Mr. Munjal Shah, Co-Founder and CEO of Hippocratic AI, said, 'We're proud to partner with Burjeel Holdings, one of the most respected healthcare systems in the region. This partnership supports our shared mission of achieving healthcare abundance. Our empathic genAI agents are designed to create a more compassionate and effective patient experience. Together, we will tailor our solutions to meet the specific needs of the communities we serve.' The partnership focuses on expanding the deployment of these genAI healthcare agents across Burjeel Holdings' facilities, ensuring that healthcare providers can access the latest advancements in technology and patient support. Incorporating AI technologies into the complex care environment aligns with Burjeel Holdings' commitment to transforming healthcare delivery across critical areas. Mr. John Sunil, Group CEO of Burjeel Holdings, said, "At Burjeel Holdings, we believe that the future of healthcare lies in the perfect harmony between cutting-edge technology and personalized care. Our partnership with Hippocratic AI is a testament to our ongoing mission to leverage AI to improve patient experience, efficiency, reduce wait times, and ultimately provide better health outcomes for our patients." This collaboration reflects a shared vision: harnessing safety-focused generative AI to support healthcare systems, ease staffing challenges, and deliver hyper personalized, compassionate care - advancing the collective goal of healthcare abundance.
Web Release
16-04-2025
- Business
- Web Release
Burjeel Holdings to Revolutionize Cancer Care in MENA with 90% Cheaper CAR-T Therapy
By Editor_wr On Apr 16, 2025 In a groundbreaking move set to transform cancer treatment access across MENA, Burjeel Holdings has partnered with U.S.-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs. Caring Cross will support Burjeel Holdings with the necessary technology, materials, and specialized training to establish a local ecosystem for manufacturing CAR-T therapies, as well as providing lentiviral vectors essential for clinical development. The collaboration was announced at Abu Dhabi Global Health Week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings. CAR-T therapies, which reprogram a patient's immune cells to attack cancer cells, have shown remarkable success in treating certain blood cancers like leukemia and lymphoma. However, with costs ranging from US$350,000 to over $1 million in global markets, access remains severely restricted. The partnership seeks to dismantle this barrier by enabling the production of CAR-T therapies at a fraction of the current price, making these treatments accessible to a vastly broader patient population in MENA and beyond. Enhancing Access to Life-Saving Cancer Care The collaboration will position Burjeel Holdings as a regional hub for advanced cell and gene therapies. By enabling local, point-of-care production of patient-specific therapies, the initiative will expand the reach of these therapies to underserved populations across the MENA region. The first phase of the program will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future. 'We are honored to partner with Caring Cross, whose expertise in CAR-T cell therapy production technology will enable us to provide affordable, life-saving treatments to our communities and beyond. This partnership is a pivotal step in our commitment to advancing medical innovation and expanding access to critical healthcare services,' said John Sunil, Group CEO of Burjeel Holdings. 'We are excited to partner with Burjeel Holdings to improve access to CAR-T cell and other ATMPs for patients across their hospital networks in the MENA region,' said Boro Dropuli?, Executive Director of Caring Cross. 'This collaboration advances our mission to make these groundbreaking treatments accessible and affordable around the world. By combining our innovative technologies with Burjeel Holdings hospital network and infrastructure, we intend to significantly improve patient access with a sustainable and cost-effective model.' Building Local Capabilities and Expanding Impact This initiative reflects Burjeel Holdings' broader mission to expand access to high-quality healthcare in regions that need it most. The partnership will focus on training and developing local healthcare providers, ensuring the sustainable and scalable delivery of CAR-T therapies across MENA, India, and globally. 'Our collaboration is operating at the cutting edge of medical innovation, opening doors to biological therapies not just in MENA, but also in emerging markets like India and other parts of Asia. This is a monumental stride in enhancing access to cancer treatments and addressing the escalating need for advanced healthcare globally,' said Dr. Ajlan Al Zaki, Director of the Hematology Oncology & Cellular Therapy Center at Burjeel Hospital Abu Dhabi. This partnership reinforces Burjeel Holdings' commitment to transforming the healthcare landscape in MENA and beyond, offering hope and tangible solutions to millions of patients who previously lacked access to life-saving treatments. Prev Post Salik To Launch Automatic Parking At 18 Dubai Locations Comments are closed.
Al Bawaba
16-04-2025
- Business
- Al Bawaba
Burjeel Holdings to Revolutionize Cancer Care in MENA with 90% Cheaper CAR-T Therapy
In a groundbreaking move set to transform cancer treatment access across MENA, Burjeel Holdings has partnered with U.S.-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs. Caring Cross will support Burjeel Holdings with the necessary technology, materials, and specialized training to establish a local ecosystem for manufacturing CAR-T therapies, as well as providing lentiviral vectors essential for clinical development. The collaboration was announced at Abu Dhabi Global Health Week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings. CAR-T therapies, which reprogram a patient's immune cells to attack cancer cells, have shown remarkable success in treating certain blood cancers like leukemia and lymphoma. However, with costs ranging from US$350,000 to over $1 million in global markets, access remains severely restricted. The partnership seeks to dismantle this barrier by enabling the production of CAR-T therapies at a fraction of the current price, making these treatments accessible to a vastly broader patient population in MENA and beyond. Enhancing Access to Life-Saving Cancer CareThe collaboration will position Burjeel Holdings as a regional hub for advanced cell and gene therapies. By enabling local, point-of-care production of patient-specific therapies, the initiative will expand the reach of these therapies to underserved populations across the MENA region. The first phase of the program will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future. 'We are honored to partner with Caring Cross, whose expertise in CAR-T cell therapy production technology will enable us to provide affordable, life-saving treatments to our communities and beyond. This partnership is a pivotal step in our commitment to advancing medical innovation and expanding access to critical healthcare services,' said John Sunil, Group CEO of Burjeel Holdings. 'We are excited to partner with Burjeel Holdings to improve access to CAR-T cell and other ATMPs for patients across their hospital networks in the MENA region,' said Boro Dropulić, Executive Director of Caring Cross. 'This collaboration advances our mission to make these groundbreaking treatments accessible and affordable around the world. By combining our innovative technologies with Burjeel Holdings hospital network and infrastructure, we intend to significantly improve patient access with a sustainable and cost-effective model.' Building Local Capabilities and Expanding Impact This initiative reflects Burjeel Holdings' broader mission to expand access to high-quality healthcare in regions that need it most. The partnership will focus on training and developing local healthcare providers, ensuring the sustainable and scalable delivery of CAR-T therapies across MENA, India, and globally. 'Our collaboration is operating at the cutting edge of medical innovation, opening doors to biological therapies not just in MENA, but also in emerging markets like India and other parts of Asia. This is a monumental stride in enhancing access to cancer treatments and addressing the escalating need for advanced healthcare globally,' said Dr. Ajlan Al Zaki, Director of the Hematology Oncology & Cellular Therapy Center at Burjeel Hospital Abu Dhabi. This partnership reinforces Burjeel Holdings' commitment to transforming the healthcare landscape in MENA and beyond, offering hope and tangible solutions to millions of patients who previously lacked access to life-saving treatments. © 2000 - 2025 Al Bawaba (
Zawya
15-04-2025
- Business
- Zawya
Burjeel Holdings to revolutionize cancer care in MENA with 90% cheaper CAR-T therapy
The Collaboration was Announced at Abu Dhabi Global Health Week Abu Dhabi: In a groundbreaking move set to transform cancer treatment access across MENA, Burjeel Holdings has partnered with U.S.-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs. Caring Cross will support Burjeel Holdings with the necessary technology, materials, and specialized training to establish a local ecosystem for manufacturing CAR-T therapies, as well as providing lentiviral vectors essential for clinical development. The collaboration was announced at Abu Dhabi Global Health Week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings. CAR-T therapies, which reprogram a patient's immune cells to attack cancer cells, have shown remarkable success in treating certain blood cancers like leukemia and lymphoma. However, with costs ranging from US$350,000 to over $1 million in global markets, access remains severely restricted. The partnership seeks to dismantle this barrier by enabling the production of CAR-T therapies at a fraction of the current price, making these treatments accessible to a vastly broader patient population in MENA and beyond. Enhancing Access to Life-Saving Cancer Care The collaboration will position Burjeel Holdings as a regional hub for advanced cell and gene therapies. By enabling local, point-of-care production of patient-specific therapies, the initiative will expand the reach of these therapies to underserved populations across the MENA region. The first phase of the program will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future. 'We are honored to partner with Caring Cross, whose expertise in CAR-T cell therapy production technology will enable us to provide affordable, life-saving treatments to our communities and beyond. This partnership is a pivotal step in our commitment to advancing medical innovation and expanding access to critical healthcare services,' said John Sunil, Group CEO of Burjeel Holdings. 'We are excited to partner with Burjeel Holdings to improve access to CAR-T cell and other ATMPs for patients across their hospital networks in the MENA region,' said Boro Dropulić, Executive Director of Caring Cross. 'This collaboration advances our mission to make these groundbreaking treatments accessible and affordable around the world. By combining our innovative technologies with Burjeel Holdings hospital network and infrastructure, we intend to significantly improve patient access with a sustainable and cost-effective model.' Building Local Capabilities and Expanding Impact This initiative reflects Burjeel Holdings' broader mission to expand access to high-quality healthcare in regions that need it most. The partnership will focus on training and developing local healthcare providers, ensuring the sustainable and scalable delivery of CAR-T therapies across MENA, India, and globally. 'Our collaboration is operating at the cutting edge of medical innovation, opening doors to biological therapies not just in MENA, but also in emerging markets like India and other parts of Asia. This is a monumental stride in enhancing access to cancer treatments and addressing the escalating need for advanced healthcare globally,' said Dr. Ajlan Al Zaki, Director of the Hematology Oncology & Cellular Therapy Center at Burjeel Hospital Abu Dhabi. This partnership reinforces Burjeel Holdings' commitment to transforming the healthcare landscape in MENA and beyond, offering hope and tangible solutions to millions of patients who previously lacked access to life-saving treatments.
